Galapagos NV
Encyclopedia
Galapagos is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech, with seven clinical and over 50 small molecule discovery/pre-clinical programs. Galapagos has established risk sharing alliances with GSK
, Janssen Pharmaceutica
, Eli Lilly and Company
, Roche and Servier. Through an alliance with MorphoSys
, Galapagos is also developing new antibody therapies in bone and joint diseases. Including its BioFocus and Argenta service operations, Galapagos has more than 800 employees and operates facilities in seven countries, with global headquarters in Mechelen
, Belgium
.
and Tibotec
. From the start, Galapagos has operated a hybrid business model, combining internal discovery programs with service activities. In 2002 the Company raised €23.4 million in a private placement. In May 2005, the Company raised €22.4 million through its initial public offering on the Euronext Brussels and Euronext Amsterdam stock exchanges (ticker symbol: GLPG). Galapagos raised a combined €90 million through private placements in 2006, 2009 and 2010 and an additional €4.4 million through an equity investment by GlaxoSmithKline in 2007. Through a Level 1 ADR listing in the US, Galapagos is traded on the U.S. OTC market under the ticker symbol GLPYY.
R&D division
In December 2006 Galapagos acquired ProSkelia from ProStrakan through an all-share transaction. With ProSkelia, Galapagos obtained R&D operations and a product portfolio of products focused on musculoskeletal diseases (osteoporosis, cachexia and bone metastasis). In September 2010, Galapagos acquired GlaxoSmithKline’s former research center in Zagreb, Croatia.
Galapagos has entered into long term alliances with large pharma companies for a number of its research programs. These risk sharing alliances have enabled Galapagos to build a pipeline of seven clinical programs and more than 50 discovery/preclinical programs, based predominantly on proprietary targets that the Company has identified. Through this alliance strategy, Galapagos is eligible to receive approximately €2.5 billion in success-dependent milestone revenue plus up to double-digit royalties on commercial products.
Service division
In 2005 Galapagos acquired BioFocus, a drug discovery company based in Saffron Walden, UK. In 2006, Galapagos acquired the drug discovery operations of Discovery Partners International and Inpharmatica Ltd. Galapagos then acquired the structure-based drug discovery business of Sareum Holdings plc in 2008. These strategic acquisitions enable BioFocus to offer a full suite of target-to-candidate drug discovery products and services, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
In February 2010, Galapagos acquired Argenta's service operations. Together, Argenta and BioFocus form one of the world's largest drug discovery service operations, with 350 employees and an estimated €70 M in annual turnover.
BioFocus website
Argenta website
GSK
GSK could refer to:* Get Started Kit * GlaxoSmithKline , a multinational pharmaceutical corporation* Global Security Kit, a cryptographic programming library by IBM* GSK-3, a protein kinase...
, Janssen Pharmaceutica
Janssen Pharmaceutica
Janssen Pharmaceutica is pharmaceutical company, established in Belgium in 1953 by Paul Janssen. Its headquarters are located in Beerse, in the Campine region of the province of Antwerp, Belgium. It was created not as a subsidiary of a chemical factory but solely with the aim of conducting...
, Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical company. Eli Lilly's global headquarters is located in Indianapolis, Indiana, in the United States...
, Roche and Servier. Through an alliance with MorphoSys
MorphoSys
MorphoSys AG is a German biotechnology company. It is involved in the development and research of antibodies. TecDAX has listed MorphoSys since 2004.-Technology:MorphoSys generates human antibodies that contain 100% human proteins...
, Galapagos is also developing new antibody therapies in bone and joint diseases. Including its BioFocus and Argenta service operations, Galapagos has more than 800 employees and operates facilities in seven countries, with global headquarters in Mechelen
Mechelen
Mechelen Footnote: Mechelen became known in English as 'Mechlin' from which the adjective 'Mechlinian' is derived...
, Belgium
Belgium
Belgium , officially the Kingdom of Belgium, is a federal state in Western Europe. It is a founding member of the European Union and hosts the EU's headquarters, and those of several other major international organisations such as NATO.Belgium is also a member of, or affiliated to, many...
.
History
Galapagos was founded in 1999 as a joint venture between CrucellCrucell
Crucell is a biotechnology company specializing in vaccines and antibodies. The firm, a subsidiary of Johnson & Johnson, is headquartered in Leiden, Netherlands...
and Tibotec
Tibotec
Tibotec is a pharmaceutical company with a focus on research and development for the treatment of infectious diseases such as HIV , and Hepatitis C...
. From the start, Galapagos has operated a hybrid business model, combining internal discovery programs with service activities. In 2002 the Company raised €23.4 million in a private placement. In May 2005, the Company raised €22.4 million through its initial public offering on the Euronext Brussels and Euronext Amsterdam stock exchanges (ticker symbol: GLPG). Galapagos raised a combined €90 million through private placements in 2006, 2009 and 2010 and an additional €4.4 million through an equity investment by GlaxoSmithKline in 2007. Through a Level 1 ADR listing in the US, Galapagos is traded on the U.S. OTC market under the ticker symbol GLPYY.
R&D division
In December 2006 Galapagos acquired ProSkelia from ProStrakan through an all-share transaction. With ProSkelia, Galapagos obtained R&D operations and a product portfolio of products focused on musculoskeletal diseases (osteoporosis, cachexia and bone metastasis). In September 2010, Galapagos acquired GlaxoSmithKline’s former research center in Zagreb, Croatia.
Galapagos has entered into long term alliances with large pharma companies for a number of its research programs. These risk sharing alliances have enabled Galapagos to build a pipeline of seven clinical programs and more than 50 discovery/preclinical programs, based predominantly on proprietary targets that the Company has identified. Through this alliance strategy, Galapagos is eligible to receive approximately €2.5 billion in success-dependent milestone revenue plus up to double-digit royalties on commercial products.
Service division
In 2005 Galapagos acquired BioFocus, a drug discovery company based in Saffron Walden, UK. In 2006, Galapagos acquired the drug discovery operations of Discovery Partners International and Inpharmatica Ltd. Galapagos then acquired the structure-based drug discovery business of Sareum Holdings plc in 2008. These strategic acquisitions enable BioFocus to offer a full suite of target-to-candidate drug discovery products and services, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
In February 2010, Galapagos acquired Argenta's service operations. Together, Argenta and BioFocus form one of the world's largest drug discovery service operations, with 350 employees and an estimated €70 M in annual turnover.
External links
Galapagos websiteBioFocus website
Argenta website